| Initiation of antiretroviral therapy in early asymptomatic HIV Infection et al. Lundgren JD, Gordin F, Babiker A, Emery S N Engl J Med 373, 795-807, 2015 | 3112* | 2015 |
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. RMSSPTES Buchbinder SP, Mehrota DV, Duerr A, Fitzgerald DW, Mogg D, Li P ... Lancet 2008; 372: 1881-93 (IF=39.207, citations=775)., 2008 | 1986* | 2008 |
| Plasma levels of soluble CD14 independently predict mortality in HIV infection NG Sandler, H Wand, A Roque, M Law, MC Nason, DE Nixon, ... Journal of Infectious Diseases 203 (6), 780-790, 2011 | 1262 | 2011 |
| HIV-1 vaccine induced immunity in the test of concept Step study: a case-cohort analysis. CSSE McElrath MJ, DeRosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe ... Lancet 2008; 372: 1894-1905 (IF=39.207, citations=400)., 2008 | 880* | 2008 |
| Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART study Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1133-1144, 2008 | 577 | 2008 |
| Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study BR Bavinton, AN Pinto, N Phanuphak, B Grinsztejn, GP Prestage, ... The lancet HIV 5 (8), e438-e447, 2018 | 517 | 2018 |
| Interleukin-2 therapy in patients with HIV infection INSIGHT–ESPRIT Study Group and SILCAAT Scientific Committee New England Journal of Medicine 361 (16), 1548-1559, 2009 | 426 | 2009 |
| Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III … K Samaras, H Wand, M Law, S Emery, D Cooper, A Carr Diabetes care 30 (1), 113-119, 2007 | 414 | 2007 |
| Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study A Martin, DE Smith, A Carr, C Ringland, J Amin, S Emery, J Hoy, ... Aids 18 (7), 1029-1036, 2004 | 371 | 2004 |
| Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial A Martin, M Bloch, J Amin, D Baker, DA Cooper, S Emery, A Carr, ... Clinical Infectious Diseases 49 (10), 1591-1601, 2009 | 300 | 2009 |
| No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial A Carr, C Workman, D Carey, G Rogers, A Martin, D Baker, H Wand, ... The Lancet 363 (9407), 429-438, 2004 | 286 | 2004 |
| Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant … A Duerr, Y Huang, S Buchbinder, RW Coombs, J Sanchez, C del Rio, ... The Journal of infectious diseases 206 (2), 258-266, 2012 | 277 | 2012 |
| HIV lipodystrophy: prevalence, severity and correlates of risk in Australia J Miller, A Carr, S Emery, M Law, S Mallal, D Baker, D Smith, J Kaldor, ... HIV medicine 4 (3), 293-301, 2003 | 277 | 2003 |
| Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV … Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1145-1155, 2008 | 259 | 2008 |
| Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection H Wand, A Calmy, DL Carey, K Samaras, A Carr, MG Law, DA Cooper, ... Aids 21 (18), 2445-2453, 2007 | 250 | 2007 |
| Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase JM Murray, S Emery, AD Kelleher, M Law, J Chen, DJ Hazuda, ... Aids 21 (17), 2315-2321, 2007 | 240 | 2007 |
| Risk of all-cause mortality associated with non-fatal AIDS and serious non-AIDS events among adults infected with HIV. SESEEC Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D ... AIDS 2010; 24: 697-706 (IF=6.557, citations=70)., 2010 | 232* | 2010 |
| Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation ESGESSSCES Nordell A, McKenna M, Borges AH, Duprez D, Neuhaus J, Neaton JD ... J Am Heart Assoc 2014; 3: e000844 (IF=2.882, citations=1), 2014 | 221* | 2014 |
| In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA PWG Mallon, P Unemori, R Sedwell, A Morey, M Rafferty, K William, ... Journal of Infectious Diseases 191 (10), 1686-1696, 2005 | 210 | 2005 |
| High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40) JJ Zaunders, ML Munier, N Seddiki, S Pett, S Ip, M Bailey, Y Xu, K Brown, ... The Journal of Immunology 183 (4), 2827-2836, 2009 | 193 | 2009 |
Andrew CarrSt Vincent's Hospital and University of New South Wales, SydneyVerified email at stvincents.com.au
